Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AtriCure, Inc. - Common Stock (NQ:ATRC)

55.65 +1.11 (+2.04%)
Streaming Delayed Price Updated: 12:50 PM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AtriCure, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
AtriCure CTO Sells 3,657 Shares ↗
Privitera executed the sale under a pre-established Rule 10b5-1 trading plan. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
AtriCure to Participate in the 2026 Wells Fargo Health Care Conference
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth ↗
AtriCure (NASDAQ:ATRC) said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product... 
Via MarketBeat
AtriCure (NASDAQ:ATRC) Profitability Surge Drives After-Hours Rally Despite Inline Revenue ↗
Via Chartmill
AtriCure (NASDAQ:ATRC) Q1 Results Beat Estimates as Company Reaches Key Profitability Milestone ↗
Via Chartmill
AtriCure Inc (NASDAQ:ATRC) Stock Surges on Q4 2025 Earnings Beat and Profitability Milestone ↗
Via Chartmill
Topics Earnings
News headline image
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors ↗
The sale came at $38.42 per share, slightly below the day's market close, as AtriCure maintains its $2.0 billion market cap in the medical device sector. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
An AtriCure Director Sold $905,000 in Stock. Here's How to Read It ↗
Prange's open-market disposition reduced her direct holdings by 14%, though she retains over 22,800 shares in the $2.0 billion medical device company. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
AtriCure to Participate at Upcoming Investor Conferences
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure Q2 Earnings Call Highlights ↗
AtriCure (NASDAQ:ATRC) reported double-digit revenue growth and a return to GAAP profitability in the second quarter of 2026, with management pointing to strong demand across its pain management,... 
Via MarketBeat
Topics Earnings
News headline image
AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript ↗
AtriCure (NASDAQ:ATRC) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you... 
Via Benzinga
Topics Earnings
News headline image
AtriCure Reports Second Quarter 2026 Financial Results
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Announce Second Quarter 2026 Financial Results
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook ↗
AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding... 
Via MarketBeat
News headline image
AtriCure (ATRC) Q1 2026 Earnings Transcript ↗
AtriCure (ATRC) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
AtriCure Reports First Quarter 2026 Financial Results
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Participate in the 2026 Bank of America Securities Health Care Conference
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Announce First Quarter 2026 Financial Results
From AtriCure, Inc.
Via Business Wire
News headline image
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗
This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗
This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗
Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but... 
Via The Motley Fool
Topics Derivatives ETFs Regulatory Compliance
News headline image
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching? ↗
This medical device innovator for cardiac surgery reported a notable insider sale amid a year of negative total returns. 
Via The Motley Fool
Topics Derivatives Regulatory Compliance
News headline image
AtriCure to Participate in the Citizens Life Sciences Conference
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure (ATRC) Q4 2025 Earnings Call Transcript ↗
AtriCure (ATRC) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results
From AtriCure, Inc.
Via Business Wire
News headline image
AI Diagnostics: The End of the High-Cost Imaging Era
Issued on behalf of VentriPoint Diagnostics Ltd. 
From Equity Insider
Via GlobeNewswire
What's going on in today's pre-market session ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.